Literature DB >> 24623430

Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model.

Graeme E Price1, Chia-Yun Lo, Julia A Misplon, Suzanne L Epstein.   

Abstract

UNLABELLED: Pandemic influenza is a major public health concern, but conventional strain-matched vaccines are unavailable early in a pandemic. Candidate "universal" vaccines targeting the viral antigens nucleoprotein (NP) and matrix 2 (M2), which are conserved among all influenza A virus strains and subtypes, could be manufactured in advance for use at the onset of a pandemic. These vaccines do not prevent infection but can reduce disease severity, deaths, and virus titers in the respiratory tract. We hypothesized that such immunization may reduce virus transmission from vaccinated, infected animals. To investigate this hypothesis, we studied mouse models for direct-contact and airborne transmission of H1N1 and H3N2 influenza viruses. We established conditions under which virus transmission occurs and showed that transmission efficiency is determined in part at the level of host susceptibility to infection. Our findings indicate that virus transmission between mice has both airborne and direct-contact components. Finally, we demonstrated that immunization with recombinant adenovirus vectors expressing NP and M2 significantly reduced the transmission of virus to cohoused, unimmunized mice in comparison to controls. These findings have broad implications for the impact of conserved-antigen vaccines, not only in protecting the vaccinated individual but also in protecting others by limiting influenza virus transmission and potentially reducing the size of epidemics. IMPORTANCE: Using a mouse model of influenza A virus transmission, we demonstrate that a candidate "universal" influenza vaccine both protects vaccinated animals from lethal infection and reduces the transmission of virus from vaccinated to nonvaccinated mice. This vaccine induces immunity against proteins conserved among all known influenza A virus strains and subtypes, so it could be used early in a pandemic before conventional strain-matched vaccines are available and could potentially reduce the spread of infection in the community.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24623430      PMCID: PMC4093854          DOI: 10.1128/JVI.03101-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Repeated influenza vaccination of healthy children and adults: borrow now, pay later?

Authors:  F Carrat; A Lavenu; S Cauchemez; S Deleger
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

Review 3.  Specificity of cytotoxic T lymphocytes stimulated with influenza virus. Studies in mice and humans.

Authors:  A R Townsend; A J McMichael
Journal:  Prog Allergy       Date:  1985

4.  The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses.

Authors:  Natalie Pica; Arun Iyer; Irene Ramos; Nicole M Bouvier; Ana Fernandez-Sesma; Adolfo García-Sastre; Anice C Lowen; Peter Palese; John Steel
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

Review 5.  Aerosol transmission of influenza A virus: a review of new studies.

Authors:  Raymond Tellier
Journal:  J R Soc Interface       Date:  2009-09-22       Impact factor: 4.118

6.  Transmission of avian H9N2 influenza viruses in a murine model.

Authors:  Rui Wu; Zhiwei Sui; Zewen Liu; Wangwang Liang; Keli Yang; Zhongliang Xiong; Diping Xu
Journal:  Vet Microbiol       Date:  2009-10-20       Impact factor: 3.293

7.  The mouse model is suitable for the study of viral factors governing transmission and pathogenesis of highly pathogenic avian influenza (HPAI) viruses in mammals.

Authors:  Michela Rigoni; Anna Toffan; Elisabetta Viale; Marzia Mancin; Filippo Cilloni; Elena Bertoli; Angela Salomoni; Sabrina Marciano; Adelaide Milani; Bianca Zecchin; Ilaria Capua; Giovanni Cattoli
Journal:  Vet Res       Date:  2010-06-15       Impact factor: 3.683

8.  Alterations in influenza virus pulmonary pathology induced by diethyl ether, halothane, enflurane, and pentobarbital anesthesia in mice.

Authors:  P R Knight; E Bedows; M L Nahrwold; H F Maassab; C W Smitka; M T Busch
Journal:  Anesthesiology       Date:  1983-03       Impact factor: 7.892

9.  Strategies for mitigating an influenza pandemic.

Authors:  Neil M Ferguson; Derek A T Cummings; Christophe Fraser; James C Cajka; Philip C Cooley; Donald S Burke
Journal:  Nature       Date:  2006-04-26       Impact factor: 49.962

10.  Sample size considerations for one-to-one animal transmission studies of the influenza A viruses.

Authors:  Hiroshi Nishiura; Hui-Ling Yen; Benjamin J Cowling
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more
  27 in total

1.  Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Authors:  Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

2.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

3.  Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs.

Authors:  Holly R Hughes; Amy L Vincent; Susan L Brockmeier; Phillip C Gauger; Lindomar Pena; Jefferson Santos; Douglas R Braucher; Daniel R Perez; Crystal L Loving
Journal:  Clin Vaccine Immunol       Date:  2015-08-19

Review 4.  Vaccine approaches conferring cross-protection against influenza viruses.

Authors:  Sai V Vemula; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Expert Rev Vaccines       Date:  2017-09-19       Impact factor: 5.217

5.  Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal Vaccine Candidate is Long-Lasting and Does Not Require Antibodies.

Authors:  Graeme E Price; Chia-Yun Lo; Julia A Misplon; Suzanne L Epstein
Journal:  J Virol       Date:  2022-05-31       Impact factor: 6.549

Review 6.  Molecular determinants of influenza virus pathogenesis in mice.

Authors:  Ram P Kamal; Jaqueline M Katz; Ian A York
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

Review 7.  Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.

Authors:  Suzanne L Epstein
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

8.  Age Dependence of Immunity Induced by a Candidate Universal Influenza Vaccine in Mice.

Authors:  Mayra García; Julia A Misplon; Graeme E Price; Chia-Yun Lo; Suzanne L Epstein
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

Review 9.  Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head.

Authors:  Lidewij C M Wiersma; Guus F Rimmelzwaan; Rory D de Vries
Journal:  Vaccines (Basel)       Date:  2015-03-26

10.  Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.

Authors:  Han Lei; Xiaojue Peng; Huifeng Jiao; Daxian Zhao; Jiexiu Ouyang
Journal:  Microb Cell Fact       Date:  2015-08-05       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.